 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Differential Effects of Rosiglitazone and Metformin on Inflammation and Subclinical Atherosclerosis in Patients with Type 2 Diabetes - The CHD Study"Prof. Allen J. Taylor (biography)
English - 2005-11-13 - 22 minutes
|
 | (21 slides) |
Summary :
In this talk Prof. Taylor presents the results of the CHD (Coronary Health in Diabetics) study, a randomized clinical trial on rosiglitazone vs. metformin in type 2 diabetic patients.
The insulin-sensitising antidiabetic agent metformin was shown to reduce cardiovascular outcomes in the UKPD Study, and it remains to be seen what are the effects on cardiovascular risk of the insulin-sensitising thiazolidinediones such as rosiglitazone. However, rosiglitazone and metformin have different drug mechanisms that may lead to differences in their anti-inflammatory and anti-atherosclerosis effects, and this has implications for their potential relative effects on cardiovascular outcomes, says Prof. Taylor.
In the present CHD Study, close to 100 type 2 diabetic patients with suboptimally controlled diabetes on a sulfonylurea or diet control were randomized to rosiglitazone 4mg daily or metformin 850mg twice daily. The study sought to compare changes in C-reactive protein and carotid intimal-medial thickness (CIMT) after 24 weeks of treatment. Prof. Taylor describes the study design and the observed effects of these agents in terms of glycemic control, lipids, the differential effects on CRP levels and changes in CIMT, and finally the implications of the study findings.
Copyright © 2006 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Effects of rosiglitazone vs. metformin in type 2 diabetic patients:
- -> Glycemic control
- -> Changes in CRP
- -> Changes in CIMT
- Implications of the CHD study
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
